Alector Licenses AL050 to Genentech for $100M Upfront, Extends Cash Runway into 2029
ALEC sits 67% above its 52-week low of $1.09.
Summary
Alector granted Genentech exclusive worldwide rights to its AL050 program for $100M upfront and up to $1.17B in milestones, extending cash runway into 2029.
Key Events · M&A and Partnerships · ALEC
-
Genentech License Agreement
Exclusive worldwide rights to develop and commercialize AL050, its brain-penetrant GCase enzyme replacement therapy, were granted to Genentech for $100M upfront and up to $1.17B in milestone payments plus tiered royalties.
-
Cash Runway Extended
Pro forma cash of $223.7M as of Sept 30, 2026, after the Genentech upfront and Spur payment, is expected to fund operations into 2029.
-
Spur Therapeutics Option Exercised
The option to license certain GCase patents from Spur was exercised, involving a $15M payment plus a percentage of milestone and royalty income received from Genentech.
-
Platform Validation
The deal validates the Alector Brain Carrier (ABC) blood-brain barrier platform, which is retained for the wholly owned pipeline.
Analysis · ALEC · Life Sciences
A transformative partnership with Genentech for its AL050 GCase enzyme replacement therapy has been secured, bringing $100 million upfront and up to $1.17 billion in milestones. This deal arrives after a series of clinical setbacks and the termination of the GSK collaboration, and it extends the company's cash runway into 2029. The agreement validates the Alector Brain Carrier platform and provides non-dilutive capital at a critical time.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALEC was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.1M. The 52-week trading range was $1.09 to $3.40. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.